Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will participate in two investor conferences on November 29, 2022. The first is the Evercore ISI HealthCONx Conference with a presentation at 8:00 a.m. ET, followed by the Piper Sandler 34th Annual Healthcare Conference with a presentation at 3:30 p.m. ET. Mirum is focused on rare liver diseases and has an approved treatment, LIVMARLI®, for cholestatic pruritus in Alagille syndrome patients. The company is also advancing its pipeline, including treatments for progressive familial intrahepatic cholestasis and biliary atresia.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

• Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022.
  • Company presentation Tuesday, November 29 starting at 8:00 a.m. ET
• Piper Sandler 34th Annual Healthcare Conference - November 29-30, 2022.
  • Company presentation Tuesday, November 29 starting at 3:30 p.m. ET

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. In Europe, the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older. A decision by the European Commission is expected by year-end 2022.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005128/en/

Investor Contacts:

Ian Clements, Ph.D.

investors@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

What conferences is Mirum Pharmaceuticals participating in November 2022?

Mirum Pharmaceuticals is participating in the Evercore ISI HealthCONx Conference on November 29, 2022, and the Piper Sandler 34th Annual Healthcare Conference from November 29-30, 2022.

What time will Mirum Pharmaceuticals present at the Evercore ISI HealthCONx Conference?

Mirum Pharmaceuticals will present at the Evercore ISI HealthCONx Conference on November 29, 2022, starting at 8:00 a.m. ET.

What is LIVMARLI and its significance for Mirum Pharmaceuticals?

LIVMARLI® (maralixibat) is an approved oral solution for treating cholestatic pruritus in patients with Alagille syndrome, marking a significant advancement in Mirum's efforts to address rare liver diseases.

What investigational treatments does Mirum Pharmaceuticals have in its pipeline?

Mirum Pharmaceuticals is advancing investigational treatments for progressive familial intrahepatic cholestasis and biliary atresia, including LIVMARLI and volixibat.

When can we expect a decision from the European Commission regarding LIVMARLI?

A decision from the European Commission regarding LIVMARLI is expected by year-end 2022.